SCHEMBL7903152

SCHEMBL7903152

CCN(C)Cc1nc2c(O)c(Cl)cc(Cl)c2c(=O)n1C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.33
ALDH1A1 P00352 4/20 0.32
NPSR1 Q6W5P4 2/20 0.32
TSHR P16473 2/20 0.32
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.32
GRM2 Q14416 1/20 0.31
HTT P42858 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
PIM1 P11309 2/20 0.31
CHEK1 O14757 1/20 0.31
NTRK1 P04629 1/20 0.31
FYN P06241 1/20 0.31
RET P07949 1/20 0.31
MET P08581 1/20 0.31
PDGFRB P09619 1/20 0.31
FGFR1 P11362 1/20 0.31
PDGFRA P16234 1/20 0.31
LTK P29376 1/20 0.31
MAP2K2 P36507 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7896811 0.89 KDM4E (0.37) ALDH1A1POLBSMN1; SMN2PIM1FGFR1
SCHEMBL612105 0.89 ALDH1A1 (0.34) HIF1AALDH1A1TSHRLMNAGRM2
SCHEMBL7895858 0.89 HPGD (0.34) HIF1AALDH1A1TSHRLMNAGRM2
SCHEMBL7897364 0.84 CRHR1 (0.32) NPSR1TSHRLMNAGRM2HTT
SCHEMBL7897177 0.83 HSD17B13 (0.35) HIF1AALDH1A1NPSR1LMNAHTT
SCHEMBL7903339 0.83 TSHR (0.47) ALDH1A1NPSR1TSHRLMNAHTT
SCHEMBL7905091 0.81 CHEK1 (0.50) ALDH1A1TSHRPOLBSMN1; SMN2PIM1
Pbt-434 SCHEMBL7905166 0.79 TLR7 (0.39) NPSR1LMNAFGFR1MAPTGAA
Pbt-434 SCHEMBL30080956 0.79 TLR7 (0.39) NPSR1LMNAFGFR1MAPTGAA
SCHEMBL7904142 0.79 CDK1 (0.34) ALDH1A1LMNAHTTSMN1; SMN2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 EP disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 US disclosed
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-8889695-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2014-11-18 US disclosed
US-8889695-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2014-11-18 US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 US disclosed
WO-2010071944-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NDUFV2 HIF1A 2132/4885ALDH1A1 866/4885NPSR1 1052/4885
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 HIF1A 2285/4885ALDH1A1 937/4885NPSR1 1040/4885
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 HIF1A 2285/4885ALDH1A1 937/4885NPSR1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.